Insmed

$28.09 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Insmed

Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Stock Analysis

last close $25.89
1-mo return -20.1%
3-mo return -9.2%
avg daily vol. 685.32T
52-week high 45.44
52-week low 22
market cap. $3.1B
forward pe -
annual div. -
roe -98.4%
ltg forecast -
dividend yield -
annual rev. $174M
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe